P
Parham Sadeghipour
Researcher at Iran University of Medical Sciences
Publications - 87
Citations - 1204
Parham Sadeghipour is an academic researcher from Iran University of Medical Sciences. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 10, co-authored 59 publications receiving 483 citations. Previous affiliations of Parham Sadeghipour include Tehran University of Medical Sciences & Iran University of Science and Technology.
Papers
More filters
Journal ArticleDOI
Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial.
Inspiration Investigators,Parham Sadeghipour,Azita Hajhossein Talasaz,Farid Rashidi,Babak Sharif-Kashani,Mohammad Taghi Beigmohammadi,Mohsen Farrokhpour,Seyed Hashem Sezavar,Pooya Payandemehr,Ali Dabbagh,Keivan Gohari Moghadam,Sepehr Jamalkhani,Hossein Khalili,Mahdi Yadollahzadeh,Taghi Riahi,Parisa Rezaeifar,Ouria Tahamtan,Samira Matin,Atefeh Abedini,Somayeh Lookzadeh,Hamid Reza Rahmani,Elnaz Zoghi,Keyhan Mohammadi,Pardis Sadeghipour,Homa Abri,Sanaz Hariri Tabrizi,Seyed Masoud Mousavian,Shaghayegh Shahmirzaei,Hooman Bakhshandeh,Ahmad Amin,Farnaz Rafiee,Elahe Baghizadeh,Bahram Mohebbi,Seyed Ehsan Parhizgar,Rasoul Aliannejad,Vahid Eslami,Alireza Kashefizadeh,Hessam Kakavand,Seyed Hossein Hosseini,Shadi Shafaghi,Samrand Fattah Ghazi,Atabak Najafi,David Jiménez,Aakriti Gupta,Aakriti Gupta,Mahesh V. Madhavan,Sanjum S. Sethi,Sahil A. Parikh,Manuel Monreal,Naser Hadavand,Alireza Hajighasemi,Majid Maleki,Saeed Sadeghian,Gregory Piazza,Ajay J. Kirtane,Benjamin W. Van Tassell,Paul P. Dobesh,Gregg W. Stone,Gregory Y.H. Lip,Gregory Y.H. Lip,Harlan M. Krumholz,Samuel Z. Goldhaber,Behnood Bikdeli,Behnood Bikdeli +63 more
TL;DR: In this paper, the authors evaluated the effects of intermediate-dose vs standard-dose prophylactic anticoagulation among patients with COVID-19 admitted to the intensive care unit (ICU).
Journal ArticleDOI
Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review.
Azita Hajhossein Talasaz,Parham Sadeghipour,Hessam Kakavand,Maryam Aghakouchakzadeh,Elaheh Kordzadeh-Kermani,Benjamin W. Van Tassell,Azin Gheymati,Hamid Ariannejad,Seyed Hossein Hosseini,Sepehr Jamalkhani,Michelle Sholzberg,Manuel Monreal,David Jiménez,Gregory Piazza,Sahil A. Parikh,Ajay J. Kirtane,John W. Eikelboom,Jean M. Connors,Beverley J. Hunt,Stavros Konstantinides,Mary Cushman,Jeffrey I. Weitz,Gregg W. Stone,Harlan M. Krumholz,Gregory Y.H. Lip,Samuel Z. Goldhaber,Behnood Bikdeli +26 more
TL;DR: In this paper, a variety of antithrombotic agents, doses, and durations of therapy are assessed in ongoing randomized controlled trials (RCTs) that focus on outpatients, hospitalized patients in medical wards, and patients critically ill with COVID-19.
Journal ArticleDOI
Antibiotics for treating human brucellosis
TL;DR: The pooled analysis did not demonstrate any significant difference between two regimens in terms of relapse and symptom persistence, but showed a non-significant higher risk of minor adverse reactions in doxycycline plus rifampicin (RR 1.80, 95% CI 0.99 to 1.92).
Journal ArticleDOI
International Prospective Registry of Acute Coronary Syndromes in Patients With COVID-19.
Thomas A Kite,Peter Ludman,Chris P Gale,Jianhua Wu,Adriano Caixeta,Jacques Mansourati,Manel Sabaté,Pilar Jiménez-Quevedo,Luciano Candilio,Parham Sadeghipour,Angel M. Iniesta,Stephen P. Hoole,Nicholas D. Palmer,Albert Ariza-Solé,Alim Namitokov,Héctor Hugo Escutia-Cuevas,Flavien Vincent,Otilia Tica,Mzee Ngunga,Imad Meray,Andrew Morrow,Minhaj Arefin,Steven Lindsay,Ghada Kazamel,Vinoda Sharma,Aly Saad,Gianfranco Sinagra,Federico Ariel Sanchez,Marek Roik,Stefano Savonitto,Marija Vavlukis,Shankar Sangaraju,Iqbal S. Malik,Sharon Kean,Nick Curzen,Nick Curzen,Colin Berry,Gregg W. Stone,Bernard J. Gersh,Anthony H. Gershlick +39 more
TL;DR: In this article, the authors report the demographics, angiographic findings, and in-hospital outcomes of COVID-19 patients and compare these with pre-COVID19 cohorts.
Journal ArticleDOI
Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studies.
Behnood Bikdeli,Azita Hajhossein Talasaz,Farid Rashidi,Babak Sharif-Kashani,Mohsen Farrokhpour,Hooman Bakhshandeh,S H Sezavar,Ali Dabbagh,Mohammad Taghi Beigmohammadi,Pooya Payandemehr,Mahdi Yadollahzadeh,Taghi Riahi,Hossein Khalili,Sepehr Jamalkhani,Parisa Rezaeifar,Atefeh Abedini,Somayeh Lookzadeh,Shaghayegh Shahmirzaei,Ouria Tahamtan,Samira Matin,Ahmad Amin,Seyed Ehsan Parhizgar,David Jiménez,Aakriti Gupta,Mahesh V. Madhavan,Sahil A. Parikh,Manuel Monreal,Naser Hadavand,Alireza Hajighasemi,Majid Maleki,Saeed Sadeghian,Bahram Mohebbi,Gregory Piazza,Ajay J. Kirtane,Gregory Y.H. Lip,Harlan M. Krumholz,Samuel Z. Goldhaber,Parham Sadeghipour +37 more
TL;DR: INSPIRATION and INSPIRATON-S studies will help address clinically-relevant questions for antithrombotic therapy and thromboinflammatory therapy in critically-ill patients with COVID-19 and test two independent hypotheses within a randomized control trial with 2 × 2 factorial design.